EVOKE PHARMA INC

Historical 13F Holders

Symbol
EVOK
CUSIP
30049G302
All holders as of
Q3 2025
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 30049G302 since 12/18/2024, newest first.

Filer % of Class Filed
Nantahala Capital Management, LLC 13D/A Amendment 5
0% 12/19/2025
Event 12/17/2025
Morgan Stanley 13G/A Amendment 1
0% 12/5/2025
Event 11/30/2025
Klein Roger M. 13D
10.5% 11/12/2025
Event 11/4/2025
Nantahala Capital Management, LLC 13D/A Amendment 4
16.0% 11/4/2025
Event 11/3/2025
Morgan Stanley 13G
10.5% 9/8/2025
Event 8/31/2025
Lytton, Laurence W. 13G/A Amendment 2 3.9% 5/15/2025
Event 3/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q3 15 591 k $2.94 M
2025 Q2 11 232 k $604 k
2025 Q1 11 262 k $678 k
2024 Q4 9 218 k $966 k
2024 Q3 13 208 k $995 k